South America Insulin Syringes - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The South America insulin syringes market size is expected to increase from USD 115.70 million in 2025 to USD 120.04 million in 2026 and reach USD 144.30 million by 2031, growing at a CAGR of 3.75% over 2026-2031. This report is segmented by Volume Capacity (0. 3 ML, 0. 5 ML, 1. 0 ML, Other), Insulin Concentration (U-100, U-500, Other), Diabetes Type (Type 1, Type 2, Gestational), End User (Hospitals, Home-Care, Diabetes Centers, Other), Distribution Channel (Hospital, Retail, Online Pharmacies, Other), and Geography (Brazil, Argentina, Colombia, Chile, Peru, Rest of South America). Forecasts are in Value (USD).

South America Insulin Syringes Market Trends and Insights

Rising Diabetes Prevalence and Insulin Treatment Volumes

Diabetes prevalence remains the main volume driver for the South America insulin syringes market. The International Diabetes Federation estimated that South and Central America had 35 million adults aged 20-79 living with diabetes in 2024, and projected this number to reach 52 million by 2050. The same source reported that 30.4% of adults with diabetes in the region were undiagnosed, which leaves a substantial group outside regular treatment and supply systems. Greater diagnostic coverage can bring more people into insulin treatment through public clinics and community programs. In Brazil, diabetes affected an estimated 20 million people, or 10.2% of the population, in 2025, supporting large-scale demand for essential diabetes supplies. The South America insulin syringes market is tied to this patient base because many newly treated patients will continue to use vial-and-syringe protocols where cost and procurement practices favor them.

Cost Advantage of Vial-and-Syringe Therapy in Price-Sensitive Care

Vial-and-syringe therapy retains a cost advantage in public care systems across the region. Brazil's public health system uses competitive procurement processes that support purchases of standard insulin syringes for routine care. Pen cartridges also require reusable applicators, training, and distribution arrangements that can raise the initial cost of treatment. These requirements are especially difficult for underfunded primary care units and areas where cold-chain logistics are limited. Brazil's 2026 transition program initially focused on children, adolescents, and people aged 80 or older in 4 states, rather than the full insulin-using population. The South America insulin syringes market consequently retains a broad installed base even as pen-based therapy expands in selected groups.

Migration Toward Insulin Pens and Automated Delivery Systems

The migration toward insulin pens and automated delivery systems is the strongest structural restraint on the South America insulin syringes market. Argentina's Resolution 2091/2025 expanded mandatory coverage for pump consumables and accessories, supporting broader access to device-based diabetes care. Brazil's Ministry of Health began a glargine transition in 4 pilot states in February 2026 and included reusable pen applicators in the program. Training health professionals in pen-based protocols can make later adoption easier as programs expand. Cold-chain needs and higher treatment costs still limit the replacement of syringes in many public settings. The effect is therefore uneven across income groups, cities, and clinical settings, but the direction of device adoption is clear.

Other drivers and restraints analyzed in the detailed report include:

• Public Procurement, Supply Localization, and Essential-Medicine Access Programs
• Home-Based Diabetes Management and Dose-Accuracy Requirements
• Price Compression in Public and Institutional Tenders

Segment Analysis

The 0.5 mL segment held 44.31% of the South America insulin syringes market share in 2025. Its capacity suits common U-100 insulin doses and supports its use in routine Type 2 diabetes care. Standardized public protocols in Brazil, Colombia, Chile, and Peru support recurring demand for this format. The 0.3 mL segment serves pediatric and Type 1 patients who need smaller doses and fine graduations. Other volume capacities address more limited clinical needs. These formats remain relevant where dose precision is more important than broad institutional volume.

The 1.0 mL segment is forecast to grow at a 5.18% CAGR through 2031. This is the strongest growth rate in the volume-capacity group because higher-dose and concentrated insulin regimens need larger delivery capacity. A larger barrel can reduce the need to divide treatment into multiple injections. Low-dead-space designs can also reduce the amount of insulin left in the syringe after injection. ISO 8537 sets requirements for sterile single-use insulin syringes and supports a consistent quality baseline for institutional buyers. Manufacturers that combine clear markings with low-dead-space features can address this developing need within the South America insulin syringes market.

U-100 held 69.24% of the South America insulin syringes market share in 2025. It remains the standard concentration across most public and private care settings in the region. Hospital pharmacies and distributors regularly stock U-100-calibrated products as routine supplies. This established product base gives the segment a stable role in procurement and retail distribution. Other insulin concentrations, including U-300 products delivered through dedicated pens, have a smaller role in syringe-specific demand. The segment's large base keeps it central to product portfolios and tender planning.

U-500 is forecast to expand at a 5.22% CAGR through 2031. The American Diabetes Association's 2025 guidance addresses the use of concentrated insulin for patients with high daily insulin requirements. Clear calibration is important because these products contain more units in a smaller liquid volume. Dedicated U-500 syringes can help reduce dose-preparation errors for patients requiring concentrated therapy. Embecta offers a U-500 Ultra-Fine syringe with 5-unit increment markings and a fixed needle, showing the product specificity that this use requires. The South America insulin syringes market has room for suppliers that provide education and accurate dosing tools alongside concentrated insulin products.

Complete Report Scope:

• By Volume Capacity
  • 0.3 mL
  • 0.5 mL
  • 1.0 mL
  • Other Volume Capacities
• By Insulin Concentration
  • U-100
  • U-500
  • Other Insulin Concentrations
• By Diabetes Type
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
• By End User
  • Hospitals and Clinics
  • Home-Care Settings
  • Diabetes Centers and Pharmacies
  • Other End Users
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies and E-Commerce
  • Other Distribution Channels
• By Country
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America

List of Companies Covered in this Report:

• AdvaCare
• Allison Medical, Inc.
• B. Braun
• Beckton Dickinson
• Cardinal Health
• embecta Corp.
• Exelint International Co.
• Gerresheimer
• Hindustan Syringes & Medical Devices Ltd.
• Medline Industries
• Nipro
• Poly Medicure
• Retractable Technologies
• Smiths Group
• Sol-Millennium Medical, Inc.
• TecMed AG
• Terumo
• Ultimed, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support